Terns Pharma unveils positive interim output in Phase 1 TERN-201 trial
Category: #health  By Pankaj Singh  Date: 2019-08-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Terns Pharma unveils positive interim output in Phase 1 TERN-201 trial
  • Outputs from single ascending dose specify that TERN-201 is well tolerated and generally safe & can inhibit plasma SSAO activity.
     
  • This trial has now transitioned onto the next level; multiple-ascending dose phase.

Terns Pharmaceuticals, Inc., an international biopharmaceutical company aimed at developing and discovering innovative therapies to treat cancer and non-alcoholic steatohepatitis (NASH), reportedly announced interim outputs of, currently under progress, clinical trial of TERN-201, an inhibitor of Semicarbazide-Sensitive Amine Oxidase (SSAO), being made for NASH treatment.

Interim data of first clinical study of TERN-201 tells that single, oral TERN-201 administrations were well handled with no important safety findings or any adverse events experienced that would lead to discontinuation. Every dose level studied showed reduction from baseline in SSAO activity of plasma that was maintained up to a week after the single dose TERN-201 administration. Study has now transitioned to multiple dose phase based on these outputs.

Chief Medical Officer of Terns, Erin Quirk, M.D. stated that the data seen till date from the clinical study in Phase 1 of TERN-201 has been encouraging and showed that TERN-201 is capable of being a therapy to treat liver fibrosis and NASH. Terns has further advanced two compounds into clinical development this year with TERN-101, a FXR agonist, and Tern-201 in current studies.

Quirk added that the company looks forward to check further outcomes from Phase 1 studies of TERN-201 and TERN-101 in this year as the company progresses towards its goal of unveiling effective and safe combination treatments for NASH.

Initially, TERN-201 was developed and discovered by Eli Lilly & Company. Terns made a global exclusive deal with Eli Lilly last year to manufacture, develop and commercialize TERN-201 for treating NASH. In Vienna, at International Liver CongressTM 2019, Terns presented preclinical information expressing that TERN-201 enhances NAFLD Activity Score (NAS) & fibrosis in rodent subjects of NASH.

 

Credit Source:

https://www.ternspharma.com/8-13-19-terns-announces-positive-interim-results-from-ongoing-phase-1-clinical-trial-of-tern-201

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Standard Chartered & SAP Ariba team up to simplify financial solutions
Standard Chartered & SAP Ariba team up to simplify financial solutions
By Pankaj Singh

The partnership is planned to boost digitalization of whole supply chain, improving accuracy, transparency and efficiency for suppliers and buyers alike.   SAP Ariba & Standard Chartered are focused towards supporting sustainable financi...

Sun Pharma signs pact with CMS for generic drug sales in China
Sun Pharma signs pact with CMS for generic drug sales in China
By Pankaj Singh

The pharmaceutical company has entered into an agreement with China Medical System Holdings to manufacture and manage 7 generic products in Mainland China.   The company shares rose to 4.69% to hit a day high of Rs. 434.20 on the B...

737 Max crashes prevent Boeing from launching 777X long-haul jet
737 Max crashes prevent Boeing from launching 777X long-haul jet
By Pankaj Singh

Boeing has been suffering billions of dollars in losses resulting from the 737 Max crisis Boeing has reportedly been delaying the launch of 777X long-haul jet, as the company spends its resources in handling a crisis following the crash of two of it...